Bioverativ Company Profile (NASDAQ:BIVV)

Bioverativ trades on the NASDAQ under the ticker symbol "BIVV."

14 equities research analysts have issued 12-month price targets for Bioverativ's stock. Their forecasts range from $41.00 to $65.00. On average, they expect Bioverativ's share price to reach $55.42 in the next twelve months. View Analyst Ratings for Bioverativ.

Here are some recent quotes from research analysts about Bioverativ stock:

• 1. According to Zacks Investment Research, "Bioverativ Inc. is a biotechnology company. It focuses on the discovery, research, development, and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders. Bioverativ Inc. is based in Waltham, United States. " (5/16/2017)
• 2. Stifel Nicolaus analysts commented, "On Friday Bioverativ reported FY16 earnings that included revenue of $887.4 million and net income of $439.6 million. As Biogen reported FY16 numbers that included the Eloctate and Alprolix sales, revenue was in-line with our expectations while expenses were slightly lower in addition to a one-time income tax benefit of $147.7 million. Based on this slightly better than expected expense line, we are raising our target price from $54 to $57. Key questions remain concerning the future research and development spend - which seems slightly high for the collection of clinical trials and selling, general & administrative expenses that decreased Y/Y. We note our change in target price is derived principally from less 2016 SG&A spend than expected ' leaving room for additional PT increase if the R&D line decreases as well. One of the features we like about Bioverativ is the pipeline that seems both interesting and relatively reduced risk and the company anticipates launching a Phase I trial of BIVV001 during 2H17." (3/27/2017)
• 3. Credit Suisse Group analysts commented, "We are initiating coverage of Bioverativ with an Underperform rating and $45 target price. We think the company's current valuation does not reflect enough risk from new long-acting therapies and novel pipeline competitors: Bioverativ is a pure-play hemophilia company that was spun off from Biogen in early 2017 with commercial assets (Eloctate and Alprolix). We think over the next few years that novel products will emerge from competitors that will pressure sales for its products. Although BIVV has pipeline assets similar to competitors, we think that there is a meaningful difference in development timelines. Competitive datasets over the year could drive volatility in BIVV shares since we don't expect major pipeline catalysts from BIVV this year. If we assume no market share loss from competitors, our FV is $54/share which is limited upside from current levels. Significant upside to the stock is driven by greater confidence in the pipeline which still remains early in our opinion." (3/16/2017)
• 4. Jefferies Group LLC analysts commented, "As a spin-off of BIIB's hemophilia assets, our positive view on BIVV includes strong cash flow from hemophilia franchise sales (2017 FCF of ~$380M), expanding operating margin (to ~52% in '21 from ~39% in '16) & relatively inexpensive valuation (EV/FCF of ~12x for 2017 vs. ~14x for large-cap biotech). In addition, we see meaningful upside from corporate tax reform if materialized (~+15% to our PT at 20% tax rate vs. current ~38%)." (2/1/2017)

Bioverativ saw a increase in short interest during the month of June. As of June 15th, there was short interest totalling 4,139,061 shares, an increase of 46.0% from the May 31st total of 2,834,453 shares. Based on an average daily trading volume, of 1,028,472 shares, the short-interest ratio is presently 4.0 days. Approximately 3.9% of the company's shares are sold short.

Some companies that are related to Bioverativ include Exelixis (EXEL), TESARO (TSRO), Kite Pharma (KITE), bluebird bio (BLUE), Clovis Oncology (CLVS), Neurocrine Biosciences (NBIX), Intercept Pharmaceuticals (ICPT), Juno Therapeutics (JUNO), BeiGene (BGNE), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC (GWPH), China Biologic Products (CBPO), Agios Pharmaceuticals (AGIO), Prothena Corporation PLC (PRTA), Sarepta Therapeutics (SRPT), AveXis (AVXS), Axovant Sciences (AXON) and Spark Therapeutics (ONCE).

Bioverativ's management team includes the folowing people:

• Brian S. Posner, Independent Chairman of the Board
• John G. Cox, Chief Executive Officer, Director
• John T. Greene, Chief Financial Officer, Executive Vice President, Treasurer
• Rogerio Vivaldi Coelho M.D., Executive Vice President, Chief Global Therapeutic Operations Officer
• Lucia Celona, Executive Vice President, Chief Human Resources and Corporate Communications Officer
• Richard Brudnick, Executive Vice President - Business Development
• Andrea Marie DiFabio, Executive Vice President, Chief Legal Officer
• Diantha Duvall, Vice President - Finance, Chief Accounting Officer
• Alexander J. Denner Ph.D., Independent Director
• Louis J. Paglia, Independent Director

Bioverativ's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include VA PARTNERS I, LLC (3.80%). Company insiders that own Bioverativ stock include Alexander J Denner, Brian S Posner, Diantha Duvall and Louis J Paglia. View Institutional Ownership Trends for Bioverativ.

Shares of Bioverativ can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Bioverativ stock can currently be purchased for approximately $63.62.